In March 2022, NICE recommended pegcetacoplan for the treatment of PNH in adults who have uncontrolled anaemia despite treatment with a stable dose of a C5 inhibitor for ≥ 3 months [30]. This evidence concerns the gene C5 and paroxysmal nocturnal hemoglobinuria.